Valeo Pharma Inc. (VPHIF)
Valeo Pharma Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Kirkland, QC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $9,866. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -51.6%. Its beta of 0.81 implies it has historically moved less than the broad market.
Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to sourcing, licensing, and selling a variety of medicinal products, with a primary emphasis on respiratory, specialized, and hospital-grade generic drugs. Its extensive product lineup features prominent asthma medications like Enerzair Breezhaler (a triple-combination LABA/LAMA/ICS) and Atectura Breezhaler (a dual-combination LABA/ICS). The company also offers Redesca, crucial for preventing and treating deep vein thrombosis and pulmonary embolism. For neurological conditions, Valeo markets Onstryv, an add-on treatment for Idiopathic Parkinson's Disease in patients on stable Levodopa, and Benztropine, an anticholinergic for PD. Pain management is addressed with M-Eslon, an extended-release morphine sulfate, while Yondelis targets soft tissue sarcoma. Beyond these, the portfolio includes Hesperco, an immune-supporting bioflavonoid antioxidant; Ametop, a skin anesthetic used before venous procedures; Ethacrynate Sodium, a loop diuretic for high blood pressure and swelling; and Amikacin, an injectable antibiotic. Founded in 2003, Valeo Pharma Inc. is headquartered in Kirkland, Canada.
Valeo Pharma Inc. is most often compared with the following Healthcare names: